You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

PLERIXAFOR - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Drug Prices for PLERIXAFOR

See drug prices for PLERIXAFOR

Recent Clinical Trials for PLERIXAFOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Leukemia and Lymphoma SocietyPhase 1/Phase 2
St. Louis Children's Hospital FoundationPhase 1/Phase 2
Rising Tide FoundationPhase 1/Phase 2

See all PLERIXAFOR clinical trials

Pharmacology for PLERIXAFOR
Paragraph IV (Patent) Challenges for PLERIXAFOR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MOZOBIL Injection plerixafor 24 mg/1.2 mL vials (20 mg/mL) 022311 3 2012-12-17

US Patents and Regulatory Information for PLERIXAFOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal PLERIXAFOR plerixafor SOLUTION;SUBCUTANEOUS 215334-001 Jul 24, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dr Reddys PLERIXAFOR plerixafor SOLUTION;SUBCUTANEOUS 205182-001 Jul 24, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Meitheal PLERIXAFOR plerixafor SOLUTION;SUBCUTANEOUS 215698-001 Jul 24, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Eugia Pharma PLERIXAFOR plerixafor SOLUTION;SUBCUTANEOUS 213672-001 Jul 24, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Msn PLERIXAFOR plerixafor SOLUTION;SUBCUTANEOUS 211901-001 Jul 24, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Gland Pharma Ltd PLERIXAFOR plerixafor SOLUTION;SUBCUTANEOUS 206644-001 May 3, 2024 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PLERIXAFOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 ⤷  Sign Up ⤷  Sign Up
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 ⤷  Sign Up ⤷  Sign Up
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 ⤷  Sign Up ⤷  Sign Up
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for PLERIXAFOR

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Sanofi B.V. Mozobil plerixafor EMEA/H/C/001030
Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly.,
Authorised no no no 2009-07-30
Accord Healthcare S.L.U. Plerixafor Accord plerixafor EMEA/H/C/005943
Adult patientsPlerixafor Accord is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4.2).Paediatric patients (1 to less than 18 years)Plerixafor Accord is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.2).
Authorised yes no no 2022-12-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.